Department for Reproductive Medicine, University Hospital Ghent, De Pintelaan 185 - 1P4, 9000 Ghent, Belgium.
Department for Reproductive Medicine, University Hospital Ghent, De Pintelaan 185 - 1P4, 9000 Ghent, Belgium.
Reprod Biomed Online. 2014 May;28(5):560-71. doi: 10.1016/j.rbmo.2014.01.008. Epub 2014 Jan 31.
The capacity of intracytoplasmic sperm injection (ICSI) to permit almost any type of spermatozoa to fertilize oocytes has made it the most successful treatment for male factor infertility. Despite its high success rates, fertilization failure following ICSI still occurs in 1-3% of couples. Assisted oocyte activation (AOA) is being increasingly applied in human assisted reproduction to restore fertilization and pregnancy rates in couples with a history of ICSI fertilization failure. However, controversy still exists mainly because the artificial activating agents do not mimic precisely the initial physiological processes of mammalian oocyte activation, which has led to safety concerns. This review addresses the mechanism of human oocyte activation and the relatively rare phenomenon of fertilization failure after ICSI. Next, it describes the current diagnostic approaches and focuses on the application, efficiency and safety of AOA in human assisted reproduction.
胞质内单精子注射(ICSI)使几乎任何类型的精子都能够使卵子受精,这使其成为治疗男性因素不孕最成功的方法。尽管 ICSI 的成功率很高,但在 1-3%的夫妇中,ICSI 后仍会出现受精失败。辅助卵母细胞激活(AOA)在人类辅助生殖中应用越来越广泛,旨在恢复有 ICSI 受精失败史的夫妇的受精和妊娠率。然而,仍存在争议,主要是因为人工激活剂不能精确模拟哺乳动物卵母细胞激活的初始生理过程,这引起了人们对安全性的担忧。本文综述了人类卵母细胞激活的机制以及 ICSI 后相对罕见的受精失败现象。接下来,描述了当前的诊断方法,并重点介绍了 AOA 在人类辅助生殖中的应用、效率和安全性。